NEUROCRINE BIOSCIENCES INC
Nasdaq: NBIX·San Diego, California·CIK 0000914475
- Price
- $165.31
- Base IV
- $220.32
Valuation snapshot
At $165.31, the price sits between our bear case ($101.34) and base case ($220.32).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $220.32
- above today's price · range $101.34–$379.61
- Price vs base case
- 25% below
- $165.31 against $220.32
- Base case · our researched forecast, 2026-11-13See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $101.34 to bull $379.61. Values per share.
Price against each value
- Bear case
- $101.34
- Price 63% above
- No growth
- …
- —
- Base case
- $220.32
- Price 25% below
What does Neurocrine Biosciences do?
Neurocrine Biosciences develops and sells pharmaceutical treatments for patients with neurological, psychiatric, and endocrine disorders, including tardive dyskinesia and congenital adrenal hyperplasia.
It brought in $3.7B of sales in the 12 months to Sep 2026.
Led by Kyle W. Gano, Ph.D., Chief Executive Officer since 2024. Kyle W. Gano, Ph.D. — Neurocrine Biosciences
- Industry
- Healthcare
- Based in
- San Diego, California
- Trades on
- Nasdaq as NBIX
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 19¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 39¢ of every dollar.
- Research and development33¢
- Sales, marketing and admin39¢
- Everything else it takes to operate4¢
- Tax6¢
- Left as profit19¢
- Interest and other income came back in+1¢
Who pays Neurocrine Biosciences, and for what?
Neurocrine Biosciences is a biopharmaceutical company that discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. It makes money primarily by selling proprietary prescription medications through specialty pharmacy and distributor networks.
Its customers include select specialty pharmacy providers, wholesale distributors, and specialty distributors.
INGREZZA
88%An FDA-approved medicine for tardive dyskinesia and chorea associated with Huntington's disease.
CRENESSITY
11%A first-in-class FDA-approved treatment for classic congenital adrenal hyperplasia.
Other Product Sales
1%Other commercial product sales across the portfolio.
Collaboration Revenues
1%Royalties earned on partner net sales of elagolix (AbbVie) and valbenazine (Tanabe Pharma Corporation).
Where its work physically happens, beyond headquarters:
- Soleno Redwood City Office — Redwood City, United States. Former Soleno headquarters (about 18,026 sq ft leased through August 2029, plus about 17,779 sq ft of expansion space) that came with the May 2026 acquisition and was the base of the VYKAT XR business, which had $190 million of 2025 revenue, though Neurocrine's filings reviewed do not confirm its current use.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
How is the business doing?
Sales grew from $1B in 2020 to $2.9B in 2025, about 22% a year.
Running the business leaves about 24¢ of each sales dollar as operating profit, up from 16¢ in 2020.
After paying for its upkeep and new investment, it had $1B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
The company exists to discover, develop, and deliver life-changing medicines that relieve suffering for patients with serious and under-addressed disorders.
“To relieve suffering for people with great needs, but few options.”
Who is responsible for the plan?
Kyle W. Gano, Ph.D.Chief Executive OfficerLeads Neurocrine Biosciences as Chief Executive Officer and serves on its Board of Directors. As CEO he is responsible for the whole company, which earns its revenue mainly from selling its own neuroscience and endocrine medicines, such as INGREZZA and CRENESSITY.
Eric BenevichChief Commercial OfficerResponsible for commercial development, marketing and sales across Neurocrine's product portfolio. Most of Neurocrine's revenue comes from net product sales of its marketed medicines, and his function markets and sells those medicines.
Jude Onyia, Ph.D.Chief Scientific OfficerLeads Neurocrine's drug discovery and non-clinical development teams. Drug discovery and non-clinical development produce the drug candidates in Neurocrine's pipeline, which the company aims to develop into products it can sell.
Roles checked November 13, 2026.
What management says it is working on now:
Expanding Sales Teams
Completing the planned sales team expansion by the end of Q1 2026 to increase prescriber reach and accelerate market penetration for INGREZZA and CRENESSITY.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025Advancing Late-Stage Clinical Programs
Advancing comprehensive Phase 3 clinical trials for osavampator in major depressive disorder and direclidine in schizophrenia toward initial topline data.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025Scaling Discovery and Biologics Capabilities
Investing in discovery research, medicinal chemistry, and expanded modalities such as peptides, antibodies, and gene therapies to sustain early-stage pipeline flow.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025Driving Pipeline Cadence
Advancing at least four new programs into Phase 1 and two programs into Phase 2 each year to support launching about one new medicine every two years.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
- INGREZZA Net Product Sales, Full-Year 2026
- $2,825 million to $2,875 million
- Neurocrine Biosciences Reports Second Quarter 2026 Financial Results
- Phase 1 Clinical Entries, Each year
- At least 4 new programs
- Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
- Phase 2 Clinical Entries, Each year
- At least 2 new programs
- Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
- New Medicine Launches, Every two years on average
- Approximately 1 new medicine
- Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
What's changing right now?
Growth is picking up. In Q3 2026 it sold 41% more than a year earlier. The year before, quarters averaged 34%.
Its operating margin is about where it was a year ago, 30¢ per sales dollar.
Since Oct 2026 the share price has risen 13%, from $146.38 to $165.31.
Recently
November 2, 2026
VYKAT XR net product sales, full quarter changed to $107.0M
NBIX Q3 2026 8-KNovember 2, 2026
Ingrezza net product sales, quarterly changed to $801.0M
NBIX Q3 2026 8-KNovember 2, 2026
Crenessity net product sales, quarterly changed to $211.0M
NBIX Q3 2026 8-K
Coming up
First half of 2026
NBIP-2118 IND Filing and Phase 1 Entry
Planned submission of an investigational new drug application to the FDA and initiation of Phase 1 clinical testing for obesity and metabolic disorders.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025End of first quarter 2026
Sales Force Expansion Completion
Completion of the expanded commercial sales team rollout to accelerate prescriber reach for INGREZZA and CRENESSITY.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 20252027
Osavampator Phase 3 Topline Data
Expected initial topline readout from the Phase 3 clinical program evaluating osavampator in patients with major depressive disorder.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 20252027
Direclidine Phase 3 Topline Data
Expected initial topline results from the Phase 3 clinical development program evaluating direclidine in schizophrenia.
Neurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Our own estimate moved too: the base case went from $196.96 to $220.32 a share between our last two valuations. The biggest reason: VYKAT XR net product sales, full quarter moved from an unreported prior value to $107.0M, as reported in NBIX Q3 2026 8-K.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
High Product Concentration in INGREZZA
The company relies heavily on INGREZZA for the vast majority of its total revenues, meaning any decline in demand or pricing would severely harm operations.
From the company's own filingsWould hit how fast sales growNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Reimbursement and Healthcare Pricing Pressures
Government reforms like the Inflation Reduction Act, Medicare Part D redesigns, and private payor formulary restrictions could lower drug reimbursement and margins.
From the company's own filingsWould hit how much of each sale it keepsNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Commercial and Clinical Competition
Competitors market rival treatments such as AUSTEDO and COBENFY, and newer therapeutics or generic equivalents could erode market share.
From the company's own filingsWould hit how fast sales growNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Clinical Trial and Development Failures
Drug development carries substantial uncertainty, and product candidates may fail to show sufficient safety or efficacy in clinical trials.
From the company's own filingsWould hit how much it has to reinvestNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Reliance on Third-Party Contract Manufacturers
The company owns no manufacturing facilities and relies entirely on external third parties for active pharmaceutical ingredients and product supply.
From the company's own filingsWould hit how much of each sale it keepsNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Government Investigation Risks
The company received a civil investigative demand from the Department of Justice regarding INGREZZA marketing practices, which could bring penalties or restrictions.
From the company's own filingsWould hit how much of each sale it keepsNeurocrine Biosciences Inc. Form 10-K for the Year Ended December 31, 2025
Q3 included about a $20M Ingrezza benefit from customer order timing, which is expected to reverse in Q4.
From our researchWould hit how fast sales growMarketBeat Q3 call highlights
Austedo's 38% Medicare price cut from 2027 may pressure Ingrezza's pricing and formulary position.
From our researchWould hit how fast sales growInvesting.com on Austedo MFP
Is it a good business?
From 2018 to 2025 it earned between 8% and 19% on the capital invested in it, a median of 13%. Its cost of capital in the latest valuation is 7.5%; returns were above it in every one of the 8 years.
From 2012 to 2025 it earned between -38% and 36% on its shareholders' equity, a median of 8%.
Over 10 years its operating margin ranged from $17.02 to 24¢ per sales dollar, a median of 11¢. Gross margin ran from 98¢ to 99¢.
Cost of capital 7.5%
The number of shares grew 44% from 2012 to 2020, so each share owns a smaller slice of the business.
It holds $641.5M more in cash than it owes.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $165.31. Our put its value between $101.34 and $379.61, with $220.32 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $101.34
This scenario assumes Neurocrine's run of roughly 20-40% yearly sales growth cools quickly: its main drug Ingrezza levels off under Medicare price pressure, newer drugs grow more slowly than hoped, and profits stay near today's level.
Base case, $220.32
This scenario assumes Neurocrine keeps growing strongly next year as its newer drugs build on its main drug, then slows to steadier growth, with profits edging up from recent levels.
Bull case, $379.61
This scenario assumes Neurocrine's recent growth of about 40% a year carries into next year, its newer drugs become major products, and its research pipeline delivers new medicines, letting profits grow faster than sales.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects less than we do.Margin of safety: 25%
For Neurocrine Biosciences to be worth today's $165.31, sales would need to grow about 4.8% a year. We assume 11.6%. Over the last 5 years, sales grew 28.2% a year.
Or, if sales grow 11.6% as we assume, the price works with a profit margin of 24.5% (we assume 33.0%).
Keep in mind: a low price can mean investors see a risk that isn't in the filings yet. Check the Full research tab for what could go wrong.
Do you think sales can grow 4.8% a year?
Try your own numbersWe're not very sure of this range: it scores 44 out of 100 on our checks. The weakest point is historical stability.
Test the assumptions
Our base value of $220.32 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average11.6%
Next year 25.0%, then about 8%
- Operating margin33.0%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$220.32 33.3%


